Economic models in type 2 diabetes

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2105-2118

  Yi, Y ^a   Philips, Z ^a   Bergman, G ^b   Burslem, K ^c  

^a ADELPHI REAL WORLD   (United Kingdom)

^b MAPI GROUP   (Netherlands)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Diabetes mellitus; Economic modelling; Review

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE;

ADD ON THERAPY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC EVALUATION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; LACTIC ACIDOSIS; META ANALYSIS; MONTE CARLO METHOD; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TREATMENT INDICATION; WEIGHT GAIN; WEIGHT REDUCTION;

ALGORITHMS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG TOXICITY; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, ECONOMIC; UNITED STATES;

EID: 77955613044     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.494451     Document Type: Review

References (80)

1. Nixon J, Stoykova B, Glanville J, et al. The UK NHS economic evaluation database: economic issues in evaluations of health technology. Int J Technol Assess Health Care 2000;16:731-742
2. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
3. Campbell IW. Epidemiology and clinical presentation of type 2 diabetes. Value Health 2000;3:S3-6
4. The Mount Hood 4 Modelling Group. Computer modelling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-1646
5. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decisionanalytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics 2006;355-371
6. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001; 44:2140-2155
7. Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model inpatients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Therapeut 2007; 45:203-220
8. Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3. Diabetes Res Clin Pract 2000;50(Suppl. 3):S15-46
9. Chen J, Alemao E, Yin D, et al. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008;10(Suppl. 1):33-42
10. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study UKPDS Outcomes Model (UKPDS no 68). Diabetologia 2004; 47:1747-1759
11. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725-734
12. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-744
13. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093-3101
14. Mueller E, Maxion-Bergemann S, Gultyaev D, et al. Development and validation of the economic assessment of glycemic control and long-term effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219-236
15. Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50(Suppl. 3):S47-56
16. Palmer AJ, Roze S, Valentine W, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus types 1 and 2 to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):S5-26
17. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000;43:13-26
18. Tilden D, Mariz S, Bryan T, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics 2007;25:39-54
19. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health 2008;11(Suppl):S23-32
20. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmaco Economics 2007;25:253-266
21. Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Am J Health Syst Pharm 1998; 55(Suppl. 4):S24-27
22. Ramsdell JW, Grossman JA, Stephens JM, et al. A short-term costof-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. Am J Manag Care 1999; 5:1007-1024
23. Ramsdell JW, Braunstein SN, Stephens JM, et al. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. PharmacoEconomics 2003;21:819-837
24. Nicklasson L, Palmer AJ, Roze S. Simulating the long term cost-effectiveness of a combination regimen of repaglinide plus rosiglitazone vs. rosiglitazone monotherapy over a 30-year period. Value in Health 2003;6:334
25. Nicklasson L, Palmer AJ, Gall M, et al. Estimating the cost-effectiveness of repaglinide plus metformin vs. nataglinide plus metformin. Value in Health 2003;6:333-334
26. Fon F, Celaya J, Ayala C, et al. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) patients with inihibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy. Value in Health 2007;10:A254
27. Celaya J, Fon F, Ayala C, et al. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) in monotherapy. Value in Health 2007;10:A254
28. NICE. Management of type 2 diabetes management of blood glucose. Inherited Clinical Guideline G. 2002
29. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. Br Med J 2000;321:405-412
30. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. Br Med J 2000;321:412-419
31. Coyle D, Lee KM, O'Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. PharmacoEconomics 2002;20(Suppl. 1): 11-19
32. Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. PharmacoEconomics 2002;20(Suppl. 1): S43-53
33. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl. 1):S27-40
34. Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische Medizinische Wochenschrift 2000;130: 1034-1040
35. Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008;11(Suppl. 1): S43-51
36. Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmaco Economics 2002;20(Suppl. 1): S31-42
37. Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: Modelling the longterm health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869-876
38. Minshall M, Oglesby A, Wintle M, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33
39. Palmer AJ, Roze S, Valentine WJ, et al. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model. Curr Med Res Opin 2004;20(Suppl. 1):S59-66
40. Palmer AJ. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004;20:S41-51
41. Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metabol 2007;9: 103-113 (Pubitemid 44921048)
42. Ray J, Boye K, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-622
43. Ray J, Huet D, Valentine W, et al. Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. Br J Diabetes Vasc Dis 2008;8:39-44
44. Roze S, Valentine WJ, Evers T, et al. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin 2006;22:1415-1424
45. Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005;21:2063-2071
46. Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic Med 2007;24:982-1002
47. Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-290
48. Shaya FT. Clinical and economic evaluation of exenatide for formulary decisions. J Med Econ 2007;10:529-537
49. Neeser K. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. PharmacoEconomics 2004;22:321-341
50. Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-877
51. Gray AM, Clarke P. The economic analyses of the UK prospective diabetes study. Diabet Med 2008;25(Suppl. 2):S47-51
52. NICE. Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine: Technology Appraisal No. 2002
53. NICE. Type II diabetes: the management of type II diabetes (NICE clinical guideline 66). 2008
54. NICE. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. 2008
55. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metabol 2008;10(Suppl. 1):43-55
56. National Coordinating Centre for Health Technology Assessment. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Tech Assess 2007; 11;140
57. Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. PharmacoEconomics 2006;24(Suppl. 1):5-19
58. Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics 2006;24(Suppl. 1):S21-34
59. Shearer AT, Bagust A, Liebl A, et al. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. PharmacoEconomics 2006;24(Suppl. 1):S35-48
60. Shearer A, Bagust A, Ampudia B, et al. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. PharmacoEconomics 2006;24 (Suppl. 1):S49-59
61. Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes. Clin Ther 2000;22:116-127
62. Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002; 24:1690-1705
63. Ward AJ, Salas M, Caro JJ, et al. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Eff Resour Allocat 2004;2:2
64. Eddy D. Bringing health economic modelling to the 21st century. Value Health 2006;9:168-173
65. Diabetes PhD and Archimedes, 20 Available at: http://www. diabetesarchive.net/diabetesphd/archimedes.jsp [Last accessed 27 May 2010]
66. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-264
67. Lewis V, Kloer P, Prasad N, et al. The HOPE study and diabetes Heart Outcomes Prevention Evaluation. Lancet 2000;355:1182
68. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
69. Framingham Heart Study, 20 Available at: http://framingham.com/heart/ backgrnd.htm [Last accessed 27 May 2010]
70. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
71. Klein R, Klein B.E, Moss SE, et al. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984;119:54-61
72. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-230
73. Boutayeb A, Chetouani A. A critical review of mathematical models and data used in diabetology. BioMedical Engineering OnLine 2006; 5:43
74. NICE. Guidance on the use of glitazones for the treatment of type 2 diabetes, 2003
75. Warren E, Weatherley J, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Tech Assess 2004;8:25-35
76. Scottish Medicines Consortium. Sitagliptin 100 mg tablets (Januvia-) Merck, Sharpe & Dohme Limited. No. (408/07). 7 September 2007
77. Tarride JE, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. PharmacoEconomics 2010;28:255-277
78. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods For The Economic Evaluation Of Health Care Programmes, 3rd Oxford Medical Publications, 2005
79. NICE. Guide to the methods of technology appraisal, June 20,Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune 2008.pdf [Last accessed 27 May 2010]
80. NICE. Guide to the multiple technology appraisal process, October 20 Available at http://www.nice.org.uk/media/916/6B/Guide-to-the-MTAproof- 8-26-10-09.pdf [Last accessed 27 May 2010]